Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Buy
55
XBI Quote, Financials, Valuation and Earnings
Last price:
$125.50
Seasonality move
:
-2.09%
Day range:
$122.79 - $125.87
52-week range:
$66.66 - $132.09
Dividend yield:
0.36%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
9.6M
Avg. volume:
9.5M
1-year change:
34.42%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- |
|
FHLC
Fidelity MSCI Health Care Index ETF
|
-- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
-- | -- | -- | -- | -- |
|
XLV
State Street Health Care Select Sector SPDR ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XBI
State Street SPDR S&P Biotech ETF
|
$125.51 | -- | -- | -- | $0.41 | 0.36% | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
$212.57 | -- | -- | -- | $1.17 | 0% | -- |
|
FHLC
Fidelity MSCI Health Care Index ETF
|
$75.19 | -- | -- | -- | $0.27 | 1.38% | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
$110.52 | -- | -- | -- | $0.25 | 0.93% | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
$32.69 | -- | -- | -- | $0.05 | 0.68% | -- |
|
XLV
State Street Health Care Select Sector SPDR ETF
|
$157.71 | -- | -- | -- | $0.66 | 1.57% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | 0.972 | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | 0.393 | -- | -- |
|
FHLC
Fidelity MSCI Health Care Index ETF
|
-- | 0.025 | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -0.012 | -- | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
-- | 0.353 | -- | -- |
|
XLV
State Street Health Care Select Sector SPDR ETF
|
-- | -0.123 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- | -- |
|
FHLC
Fidelity MSCI Health Care Index ETF
|
-- | -- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
-- | -- | -- | -- | -- | -- |
|
XLV
State Street Health Care Select Sector SPDR ETF
|
-- | -- | -- | -- | -- | -- |
State Street SPDR S&P Biotech ETF vs. Competitors
-
Which has Higher Returns XBI or FBT?
First Trust NYSE Arca Biotechnology Index Fund has a net margin of -- compared to State Street SPDR S&P Biotech ETF's net margin of --. State Street SPDR S&P Biotech ETF's return on equity of -- beat First Trust NYSE Arca Biotechnology Index Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBIState Street SPDR S&P Biotech ETF-- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- -
What do Analysts Say About XBI or FBT?
State Street SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust NYSE Arca Biotechnology Index Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street SPDR S&P Biotech ETF has higher upside potential than First Trust NYSE Arca Biotechnology Index Fund, analysts believe State Street SPDR S&P Biotech ETF is more attractive than First Trust NYSE Arca Biotechnology Index Fund.
Company Buy Ratings Hold Ratings Sell Ratings XBIState Street SPDR S&P Biotech ETF0 0 0 FBTFirst Trust NYSE Arca Biotechnology Index Fund0 0 0 -
Is XBI or FBT More Risky?
State Street SPDR S&P Biotech ETF has a beta of 0.945, which suggesting that the stock is 5.483% less volatile than S&P 500. In comparison First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.734, suggesting its less volatile than the S&P 500 by 26.595%.
-
Which is a Better Dividend Stock XBI or FBT?
State Street SPDR S&P Biotech ETF has a quarterly dividend of $0.41 per share corresponding to a yield of 0.36%. First Trust NYSE Arca Biotechnology Index Fund offers a yield of 0% to investors and pays a quarterly dividend of $1.17 per share. State Street SPDR S&P Biotech ETF pays -- of its earnings as a dividend. First Trust NYSE Arca Biotechnology Index Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or FBT?
State Street SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than First Trust NYSE Arca Biotechnology Index Fund quarterly revenues of --. State Street SPDR S&P Biotech ETF's net income of -- is lower than First Trust NYSE Arca Biotechnology Index Fund's net income of --. Notably, State Street SPDR S&P Biotech ETF's price-to-earnings ratio is -- while First Trust NYSE Arca Biotechnology Index Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street SPDR S&P Biotech ETF is -- versus -- for First Trust NYSE Arca Biotechnology Index Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBIState Street SPDR S&P Biotech ETF-- -- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- --
-
Which has Higher Returns XBI or FHLC?
Fidelity MSCI Health Care Index ETF has a net margin of -- compared to State Street SPDR S&P Biotech ETF's net margin of --. State Street SPDR S&P Biotech ETF's return on equity of -- beat Fidelity MSCI Health Care Index ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBIState Street SPDR S&P Biotech ETF-- -- -- FHLCFidelity MSCI Health Care Index ETF-- -- -- -
What do Analysts Say About XBI or FHLC?
State Street SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Fidelity MSCI Health Care Index ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street SPDR S&P Biotech ETF has higher upside potential than Fidelity MSCI Health Care Index ETF, analysts believe State Street SPDR S&P Biotech ETF is more attractive than Fidelity MSCI Health Care Index ETF.
Company Buy Ratings Hold Ratings Sell Ratings XBIState Street SPDR S&P Biotech ETF0 0 0 FHLCFidelity MSCI Health Care Index ETF0 0 0 -
Is XBI or FHLC More Risky?
State Street SPDR S&P Biotech ETF has a beta of 0.945, which suggesting that the stock is 5.483% less volatile than S&P 500. In comparison Fidelity MSCI Health Care Index ETF has a beta of 0.695, suggesting its less volatile than the S&P 500 by 30.488%.
-
Which is a Better Dividend Stock XBI or FHLC?
State Street SPDR S&P Biotech ETF has a quarterly dividend of $0.41 per share corresponding to a yield of 0.36%. Fidelity MSCI Health Care Index ETF offers a yield of 1.38% to investors and pays a quarterly dividend of $0.27 per share. State Street SPDR S&P Biotech ETF pays -- of its earnings as a dividend. Fidelity MSCI Health Care Index ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or FHLC?
State Street SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than Fidelity MSCI Health Care Index ETF quarterly revenues of --. State Street SPDR S&P Biotech ETF's net income of -- is lower than Fidelity MSCI Health Care Index ETF's net income of --. Notably, State Street SPDR S&P Biotech ETF's price-to-earnings ratio is -- while Fidelity MSCI Health Care Index ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street SPDR S&P Biotech ETF is -- versus -- for Fidelity MSCI Health Care Index ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBIState Street SPDR S&P Biotech ETF-- -- -- -- FHLCFidelity MSCI Health Care Index ETF-- -- -- --
-
Which has Higher Returns XBI or PJP?
Invesco Pharmaceuticals ETF has a net margin of -- compared to State Street SPDR S&P Biotech ETF's net margin of --. State Street SPDR S&P Biotech ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBIState Street SPDR S&P Biotech ETF-- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- -
What do Analysts Say About XBI or PJP?
State Street SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street SPDR S&P Biotech ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe State Street SPDR S&P Biotech ETF is more attractive than Invesco Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings XBIState Street SPDR S&P Biotech ETF0 0 0 PJPInvesco Pharmaceuticals ETF0 0 0 -
Is XBI or PJP More Risky?
State Street SPDR S&P Biotech ETF has a beta of 0.945, which suggesting that the stock is 5.483% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.1%.
-
Which is a Better Dividend Stock XBI or PJP?
State Street SPDR S&P Biotech ETF has a quarterly dividend of $0.41 per share corresponding to a yield of 0.36%. Invesco Pharmaceuticals ETF offers a yield of 0.93% to investors and pays a quarterly dividend of $0.25 per share. State Street SPDR S&P Biotech ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or PJP?
State Street SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. State Street SPDR S&P Biotech ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, State Street SPDR S&P Biotech ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street SPDR S&P Biotech ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBIState Street SPDR S&P Biotech ETF-- -- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns XBI or RSPH?
Invesco S&P 500 Eql Wght Health Care ETF has a net margin of -- compared to State Street SPDR S&P Biotech ETF's net margin of --. State Street SPDR S&P Biotech ETF's return on equity of -- beat Invesco S&P 500 Eql Wght Health Care ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBIState Street SPDR S&P Biotech ETF-- -- -- RSPHInvesco S&P 500 Eql Wght Health Care ETF-- -- -- -
What do Analysts Say About XBI or RSPH?
State Street SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco S&P 500 Eql Wght Health Care ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street SPDR S&P Biotech ETF has higher upside potential than Invesco S&P 500 Eql Wght Health Care ETF, analysts believe State Street SPDR S&P Biotech ETF is more attractive than Invesco S&P 500 Eql Wght Health Care ETF.
Company Buy Ratings Hold Ratings Sell Ratings XBIState Street SPDR S&P Biotech ETF0 0 0 RSPHInvesco S&P 500 Eql Wght Health Care ETF0 0 0 -
Is XBI or RSPH More Risky?
State Street SPDR S&P Biotech ETF has a beta of 0.945, which suggesting that the stock is 5.483% less volatile than S&P 500. In comparison Invesco S&P 500 Eql Wght Health Care ETF has a beta of 0.926, suggesting its less volatile than the S&P 500 by 7.362%.
-
Which is a Better Dividend Stock XBI or RSPH?
State Street SPDR S&P Biotech ETF has a quarterly dividend of $0.41 per share corresponding to a yield of 0.36%. Invesco S&P 500 Eql Wght Health Care ETF offers a yield of 0.68% to investors and pays a quarterly dividend of $0.05 per share. State Street SPDR S&P Biotech ETF pays -- of its earnings as a dividend. Invesco S&P 500 Eql Wght Health Care ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or RSPH?
State Street SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than Invesco S&P 500 Eql Wght Health Care ETF quarterly revenues of --. State Street SPDR S&P Biotech ETF's net income of -- is lower than Invesco S&P 500 Eql Wght Health Care ETF's net income of --. Notably, State Street SPDR S&P Biotech ETF's price-to-earnings ratio is -- while Invesco S&P 500 Eql Wght Health Care ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street SPDR S&P Biotech ETF is -- versus -- for Invesco S&P 500 Eql Wght Health Care ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBIState Street SPDR S&P Biotech ETF-- -- -- -- RSPHInvesco S&P 500 Eql Wght Health Care ETF-- -- -- --
-
Which has Higher Returns XBI or XLV?
State Street Health Care Select Sector SPDR ETF has a net margin of -- compared to State Street SPDR S&P Biotech ETF's net margin of --. State Street SPDR S&P Biotech ETF's return on equity of -- beat State Street Health Care Select Sector SPDR ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBIState Street SPDR S&P Biotech ETF-- -- -- XLVState Street Health Care Select Sector SPDR ETF-- -- -- -
What do Analysts Say About XBI or XLV?
State Street SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street Health Care Select Sector SPDR ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street SPDR S&P Biotech ETF has higher upside potential than State Street Health Care Select Sector SPDR ETF, analysts believe State Street SPDR S&P Biotech ETF is more attractive than State Street Health Care Select Sector SPDR ETF.
Company Buy Ratings Hold Ratings Sell Ratings XBIState Street SPDR S&P Biotech ETF0 0 0 XLVState Street Health Care Select Sector SPDR ETF0 0 0 -
Is XBI or XLV More Risky?
State Street SPDR S&P Biotech ETF has a beta of 0.945, which suggesting that the stock is 5.483% less volatile than S&P 500. In comparison State Street Health Care Select Sector SPDR ETF has a beta of 0.656, suggesting its less volatile than the S&P 500 by 34.438%.
-
Which is a Better Dividend Stock XBI or XLV?
State Street SPDR S&P Biotech ETF has a quarterly dividend of $0.41 per share corresponding to a yield of 0.36%. State Street Health Care Select Sector SPDR ETF offers a yield of 1.57% to investors and pays a quarterly dividend of $0.66 per share. State Street SPDR S&P Biotech ETF pays -- of its earnings as a dividend. State Street Health Care Select Sector SPDR ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or XLV?
State Street SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than State Street Health Care Select Sector SPDR ETF quarterly revenues of --. State Street SPDR S&P Biotech ETF's net income of -- is lower than State Street Health Care Select Sector SPDR ETF's net income of --. Notably, State Street SPDR S&P Biotech ETF's price-to-earnings ratio is -- while State Street Health Care Select Sector SPDR ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street SPDR S&P Biotech ETF is -- versus -- for State Street Health Care Select Sector SPDR ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBIState Street SPDR S&P Biotech ETF-- -- -- -- XLVState Street Health Care Select Sector SPDR ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
